Carmustin
Carmustin Brand names, Carmustin Analogs
Carmustin Brand Names Mixture
- No information avaliable
Carmustin Chemical_Formula
C5H9Cl2N3O2
Carmustin RX_link
http://www.rxlist.com/cgi/generic3/carmustine.htm
Carmustin fda sheet
Carmustin msds (material safety sheet)
Carmustin Synthesis Reference
Johnston TP et al. J Med Chem 122:669-681(1963).
Carmustin Molecular Weight
214.049 g/mol
Carmustin Melting Point
31 oC
Carmustin H2O Solubility
< 0.1 g/100 mL at 18 °C
Carmustin State
Solid
Carmustin LogP
1.256
Carmustin Dosage Forms
Powder for solution; Wafer
Carmustin Indication
For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
Carmustin Pharmacology
Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.
Carmustin Absorption
5 to 28% bioavailability
Carmustin side effects and Toxicity
The oral LD50s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.
Carmustin Patient Information
No information avaliable
Carmustin Organisms Affected
Humans and other mammals
